Cascadian Therapeutics has obtained an exclusive license from Array BioPharma for the manufacture, development and commercialization of tucatinib (ONT-380), an orally active, reversible and selective small molecule HER2 inhibitor. The license agreement replaced a prior collaboration agreement under which Cascadian Therapeutics and Array were jointly developing tucatinib. Cascadian Therapeutics is developing tucatinib for the treatment of metastatic HER2+ breast cancer.
Cascadian Therapeutics is collaborating with Sentinel Oncology Ltd., Cambridge, UK, for the discovery of novel small molecule inhibitors of checkpoint kinase 1. Under terms of the agreement, Cascadian Therapeutics will have sole responsibility for the manufacture, development and commercialization of any compounds resulting from the collaboration. Cascadian Therapeutics currently expects to begin clinical development of a collaboration compound in early 2016.
Cascadian Therapeutics is collaborating with Adimab LLC, Lebanon, NH, for the discovery of novel antibodies against undisclosed immunotherapy targets in oncology. Cascadian Therapeutics will have sole responsibility for the manufacture, development and commercialization of any antibody products which result. The collaboration is currently at an early discovery stage.
Cascadian Therapeutics has granted an exclusive, worldwide license to Merck KGaA of Darmstadt, Germany (Merck KGaA) for the development, manufacture and commercialization of tecemotide (L-BLP25), a therapeutic vaccine directed against MUC1. Merck KGaA completed a Phase 3 trial of tecemotide in non-small cell lung cancer and does not currently plan further development of tecemotide.